Foghorn Therapeutics FHTX

$ 5.0 0.4%

Quarterly report 2024-Q3
added 11-04-2024

Foghorn Therapeutics Balance Sheet 2011-2024 | FHTX

Annual Balance Sheet Foghorn Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-35.3 M	-707 K	-42.8 M	-69.2 M	1.65 M	-33 M	-	-	-	-	-	-	-
Long Term Debt	36.6 M	45.5 M	51.3 M	19.7 M	11 M	7.03 M	-	-	-	-	-	-	-
Long Term Debt Current	8.52 M	5.97 M	6.99 M	3.98 M	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	97.7 M	78.9 M	-	-	-	-	-	-	-
Total Current Liabilities	58.4 M	55.2 M	48.7 M	18.8 M	-	-	-	-	-	-	-	-	-
Total Liabilities	363 M	405 M	423 M	109 M	110 M	82.3 M	-	-	-	-	-	-	-
Deferred Revenue	34.6 M	32.8 M	28.3 M	2.02 M	-	-	-	-	-	-	-	-	-
Retained Earnings	-472 M	-373 M	-264 M	-163 M	-94.1 M	-43 M	-	-	-	-	-	-	-
Total Assets	286 M	405 M	520 M	256 M	22.3 M	43.1 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	80.3 M	52.2 M	101 M	92.8 M	17.3 M	-	-	-	-	-	-	-	-
Book Value	-77.2 M	112 K	96.9 M	146 M	-88 M	-39.3 M	-	-	-	-	-	-	-
Total Shareholders Equity	-77.2 M	112 K	96.9 M	146 M	-88 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Foghorn Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	30.3 M	32.5 M	34.3 M	36.6 M	38.7 M	40.3 M	43.5 M	45.5 M	46.5 M	49.1 M	50.5 M	51.3 M	20 M	20 M	20 M	19.7 M	8.8 M	19.7 M	20 M	11 M	11 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	337 M	343 M	352 M	363 M	371 M	389 M	397 M	405 M	410 M	409 M	416 M	423 M	105 M	104 M	105 M	109 M	109 M	109 M	109 M	23.8 M	23.8 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	33.4 M	31.2 M	31.5 M	34.6 M	28.3 M	33.9 M	33.3 M	32.8 M	33.2 M	30.6 M	30.1 M	28.3 M	1.28 M	910 K	2.41 M	2.02 M	2.02 M	2.02 M	2.02 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-539 M	-520 M	-497 M	-472 M	-447 M	-433 M	-404 M	-373 M	-344 M	-318 M	-291 M	-264 M	-235 M	-209 M	-186 M	-163 M	-163 M	-163 M	-163 M	-94.1 M	-94.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	308 M	329 M	255 M	286 M	313 M	340 M	373 M	405 M	434 M	457 M	488 M	520 M	186 M	209 M	230 M	256 M	256 M	256 M	256 M	22.3 M	22.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	57.7 M	139 M	79.3 M	80.3 M	70.3 M	57.7 M	50.6 M	52.2 M	87.6 M	61.2 M	214 M	101 M	57.8 M	125 M	66.4 M	94.5 M	92.8 M	92.8 M	92.8 M	15 M	15 M	-	-	40.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-28.3 M	-14.3 M	-97.5 M	-77.2 M	-57.4 M	-49.4 M	-24.6 M	112 K	24.3 M	47.6 M	72.4 M	96.9 M	81 M	104 M	125 M	146 M	146 M	146 M	146 M	-1.47 M	-1.47 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-28.3 M	-14.3 M	-97.5 M	-77.2 M	-57.4 M	-49.4 M	-24.6 M	112 K	24.3 M	47.6 M	72.4 M	96.9 M	81 M	104 M	125 M	146 M	146 M	146 M	146 M	-88 M	-88 M	-61.3 M	-	-39.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency